pharmaphorum

MAY 16, 2022

Blood sugar control drug Mounjaro has been granted US regulatory approval, giving type 2 diabetics another way to help keep their glucose levels in check. These examined Mounjaro in 5mg, 10mg and 15 mg doses in five clinical trials, used either as a stand-alone therapy or as an add-on to other diabetes medicines.

Diabetes 115

Diabetes 115

pharmaphorum

NOVEMBER 8, 2022

After years of preparation, Eli Lilly is on the brink of launching a fully connected and personalised diabetes management platform, underpinned by digital technologies. Tighter glucose control is known to reduce the risk of complications of diabetes like cardiovascular disease and nerve damage affecting the eyes and extremities.

Diabetes 64

Diabetes Communication 64

Express Pharma

MAY 24, 2024

Innovent Biologics has unveiled Phase III (DREAMS-2) results for mazdutide, indicating superiority over dulaglutide in glycaemic control for type 2 diabetes (T2D) patients in China. Symbix is expected to generate global sales of $517 million by 2030. per cent from 58.460,424 in 2023 to 63,342,654 in 2028.

Diabetes 104

Diabetes 104

Pharmaceutical Business Review

APRIL 17, 2024

This partnership is set to enhance the treatment options available to diabetes patients in Brazil. We are confident that our collaboration with Biomm will provide patients in Brazil, who are living with diabetes, much needed access to advanced, high quality treatment options to help them manage the disease better.”

Diabetes 59

Diabetes Biosimilars 59

Express Pharma

AUGUST 4, 2023

At Novo Nordisk, we are dedicated to tackling chronic diseases by driving change in diabetes, obesity, rare diseases- haemophilia, growth hormone deficiency, etc., Simplifying diabetes care, awareness around obesity and related complications, CVDs and rare diseases like haemophilia continue to be the focus areas for the Indian market.

Diabetes 98

Diabetes Communication 98

European Pharmaceutical Review

DECEMBER 15, 2022

At least one million people living with type 1 and type 2 diabetes in low- to middle-income countries (LMICs), mainly Africa, are set to benefit from Eli Lilly and Company and manufacturer EVA Pharmaceutical’s new collaboration delivering a sustainable supply of high-quality, affordable human and analogue insulin to this population.

Diabetes 97

Diabetes Packaging Communication 97

Express Pharma

MAY 13, 2025

Children and young people (CYP) living in low- and middle-income countries (LMICs) face gross inequities when it comes to the diagnosis and treatment of type 1 diabetes (T1D). Without sustainable access to diabetes care, they are unable to manage this chronic condition, leading to severe outcomes that are entirely preventable.

Diabetes 89

Diabetes Biosimilars Compounding 89

European Pharmaceutical Review

AUGUST 22, 2024

Based on their rising popularity to treat type 2 diabetes and obesity, GlobalData has predicted that sales of glucagon-like peptide-1 receptor (GLP-1R) drugs will increase fourfold to an estimated $142 billion by 2030. 1 Considering the 11 approved GLP-1R drugs “generated $37.2 1 Considering the 11 approved GLP-1R drugs “generated $37.2

Diabetes 59

Diabetes 59

European Pharmaceutical Review

JANUARY 27, 2023

This is an effort which aims to improve access and address barriers to quality healthcare for 30 million people living in limited-resource settings annually, by 2030.

Communication 105

Communication Diabetes 105

Express Pharma

OCTOBER 16, 2024

billion in 2030. billion strategic collaboration with Repertoire Immune Medicines in April 2024 to develop mRNA-based tolerising vaccines for up to three autoimmune diseases, including type 1 diabetes and multiple sclerosis, along with other vaccine candidates. Bristol Myers Squibb formed a multi-year, $1.87

Vaccines 104

Vaccines Immunization Immunity Diabetes 104

pharmaphorum

JULY 14, 2022

The divestment comes as Bayer is engaged in a push to become a top ten oncology company by 2030, with its ambition driven by prostate cancer treatment Nubeqa (darolutamide), recently tipped to become a €3 billion seller. The post Bayer sells testosterone drug rights to Grünenthal for €500m appeared first on.

Diabetes 97

Diabetes 97

Express Pharma

AUGUST 8, 2024

Benemae Pharmaceutical’s benaglutide injection (Feisumei) was the first innovator approved for obesity in July 2023 in China followed by Novo Nordisk’s diabetes therapy semaglutide (Wegovy) in June 2024. Both are GLP-1 receptor agonists.

Biosimilars 102

Biosimilars Diabetes 102

Pharmaceutical Technology

JUNE 7, 2023

The recent rallying of Lilly’s market value has come as the result of two major announcements: its blockbuster type 2 diabetes (T2D) drug Mounjaro (tirzepatide) successfully completed its second final-stage trial for obesity, and its experimental treatment for Alzheimer’s disease completed its Phase III trial.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Labelling Diabetes 98

European Pharmaceutical Review

JULY 31, 2024

billion in 2023 for its obesity and diabetes blockbuster drugs Ozempic (off-label for obesity) and Wegovy respectively, facilitated the growth. Mounjaro, Zepbound, and Ozempic are expected to surpass Merck & Co’s Keytruda in global analyst consensus sales by 2030″ This is despite an “overall 1.6 Global sales of $13.9

Diabetes 52

Diabetes Labelling 52

pharmaphorum

MARCH 2, 2022

Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time. billion in 2020 to more than $16 billion by 2030, according to GlobalData.

Diabetes 52

Diabetes Communication 52

pharmaphorum

OCTOBER 17, 2022

There’s no doubt that self-injection devices have transformed the lives of people with chronic diseases like diabetes, making it easier to receive treatment, whilst also reducing risks like contamination and inappropriate use of reusable devices. Unfortunately, they have also been far from sustainable.

Community Pharmacies 64

Community Pharmacies Diabetes Pharmaceutical Companies Pharmaceutical Companies 64

Pharmafile

APRIL 3, 2023

According to the WHO, an additional 10 million health professionals will be needed by 2030. Published date: 03/04/2023 Summary: The global shortage of qualified health professionals is an increasing challenge. The demand is particularly acute in low- and middle-income countries, where health systems are already under immense pressure.

Diabetes 40

Diabetes 40

Pharmaceutical Technology

MARCH 29, 2023

This next extension beyond 2030 is a testament to the success and trust of the partnership, as well as to the high degree of confidence placed in our platforms and the complementary approach to generating a leading pipeline of highly innovative drug candidates.

Diabetes 52

Diabetes 52

Quality Matters

SEPTEMBER 9, 2024

The area is populated with apps and other software designed to treat various ailments including mental health disorders, diabetes, asthma, insomnia, substance-use disorders, and beyond. billion in 2024 to over 32 billion in 2030. Patients can often use them from the comfort of their homes.

Labelling 52

Labelling Diabetes 52

European Pharmaceutical Review

SEPTEMBER 21, 2023

billion by 2030. Gene therapy is an innovative, fast-evolving modality offering revolutionary capability in multiple disease areas. According to research by 360iresearch, the global cell & gene therapy market is estimated to value $135.04 References Blaese RM, Culver KW, Miller AD, et al. 1995; 270(5235): 475-480. cited 2023August].

Drug Development 96

Drug Development Pharmaceutical Companies Pharmaceutical Companies Diabetes 96

pharmaphorum

OCTOBER 18, 2022

Along with the Gilead fee, it could be in line for a $60 million top-up payment from Provention Bio in the fourth quarter, however, if type 1 diabetes teplizumab gets US approval. The post Gilead pledges $1.76bn to MacroGenics for bispecific cancer antibody appeared first on.

Diabetes 52

Diabetes 52

FDA Law Blog: Biosimilars

JULY 10, 2024

Another patient shared their journey with diabetes. As for the future of PGHD, many panelists were asked how they envision use of PGHD in 2030. This patient had used wearable devices on their own in the past but did not understand how to use the data to manage their health.

Diabetes 59

Diabetes 59

STAT

FEBRUARY 7, 2025

The goal, first announced in November 2023, is to improve longevity and reduce disparities caused by heart- and diabetes-related diseases by 5% by 2030 and deaths due to screenable cancers by 20% by 2030.    Read the rest…

Diabetes 181

Diabetes 181

Putting Patients First Blog

APRIL 25, 2023

Department of Health and Human Services Healthy People 2030 report, factors that influence health care disparities include social, economic, and environmental disadvantages. According to the U.S. 1 These multi-faceted influences make the patient navigation process an unpredictable experience for many.

Mayo Clinic 52

Mayo Clinic Documentation Diabetes 52

Fuld & Company Blog

MARCH 27, 2023

The background of semaglutide Nearly 20 years ago the first glucagon-like peptide 1 (GLP-1), a class of Type 2 diabetes drug that improves blood sugar, was launched, creating what is today a market worth nearly $30B. This market was estimated to be worth over $80 billion, in addition to the $30 billion diabetes market.

Diabetes 52

Diabetes Online Pharmacies Packaging Pharmaceutical Companies 52

Pharmaceutical Technology

JANUARY 11, 2023

By 2030, global spending on digital health is projected to represent 8% of all healthcare expenditure, up from 3% currently 2. Digital therapeutic apps are being built to help manage type 2 diabetes or assist with addiction. The global market size is estimated to be more than $95.3bn 1.

Health and Personal Care Stores 52

Health and Personal Care Stores Hospitals Communication Medical Records 52

Express Pharma

MAY 30, 2024

In the APAC region, several factors contribute to the increasing prevalence of neurological disorders, including ageing populations, lifestyle changes, and the rising incidence of risk factors such as hypertension and diabetes.” billion in 2030, with a compound annual growth rate (CAGR) of 117.6 These include Eisai Co. per cent and 25.5

Compounding 115

Compounding Diabetes Pharmaceutical Companies Pharmaceutical Companies 115

PharmD Live

MAY 13, 2024

Their projections indicate that approximately 10,000 people will turn 65 each day over the next 19 years, with the population of older adults expected to double to 80 million by 2030. At this rate, nearly half of the older population could be impacted by polypharmacy by 2030. Data from the U.S. in 1994 to 42.4%

Long-Term Care Facilities 105

Long-Term Care Facilities Nursing Homes Diabetes Prescription Filling 105

STAT

FEBRUARY 12, 2024

We accept all manner of confidential communications and secret dossiers … New diabetes and weight loss drugs may benefit patients undergoing hip replacement without adding to complication risks , Reuters reports, citing preliminary data released at a meeting of orthopedic surgeons.

Diabetes 290

Diabetes Vaccines Communication Hospitals 290

European Pharmaceutical Review

SEPTEMBER 7, 2022

billion market by 2030, growing from a 2020 value of around $2.4 Dr Bhat : Chronic diseases where FDCs are employed include hypertension, diabetes, Human Immunodeficiency Virus (HIV) and tuberculosis (TB). The second most commonly used pharmaceutical dosage form, capsules, are anticipated to be a $5.2 About the author.

Dosage 124

Dosage Vaccines Diabetes 124

Pharmacy Times

JUNE 9, 2025

2019;380:2020-2030. Global Initiative for Asthma. Accessed June 9, 2025. Beasley R, Holliday M, Reddell HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med.

Pharmacy Technician 29

Pharmacy Technician Compounding Pharmacies Hospitals Pharmacy Management 29

PharmD Live

OCTOBER 16, 2024

The Growing Role of Pharmacists in Chronic Care Management With an estimated 129 million Americans suffering from at least one chronic disease and costs projected to exceed $47 trillion worldwide by 2030 , the need for comprehensive, patient-centered care is more urgent than ever.

Hospitals 59

Hospitals Diabetes 59

pharmaphorum

OCTOBER 10, 2022

The pharma group said earlier this year it is hoping for eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, and thrombosis as well as PAH, that will swell its sales from in the category to $10 billion around the end of the decade.

Diabetes 52

Diabetes 52

European Pharmaceutical Review

JANUARY 10, 2025

Eleven medicines, covering key areas such as gene therapy, as well as drugs for obesity and oncology, are anticipated to attain blockbuster status or be therapeutic game-changers globally within five years to 2030, according to the 2025 edition of the Drugs to Watch report.

Diabetes 59

Diabetes Vaccines 59

Pharmacy Times

JUNE 12, 2025

The World Health Organization (WHO) has set a global goal to have 90% of girls fully vaccinated with the HPV vaccine by 2030. The vaccine also provides cross-protection against multiple high-risk HPV types beyond those directly targeted.

Vaccines 26

Vaccines Pharmacy Technician Immunization Immunity 26

Express Pharma

JANUARY 27, 2025

Asias healthcare market is on track to hit $5 trillion by 2030, driving 40 per cent of global sector growth, according to BCGs latest report. Chronic conditions such as diabetes and cancer affect the region disproportionately, and the region will have to find its unique healthcare models to manage this disease burden.

Diabetes 96

Diabetes Hospitals 96

PharmaShots

APRIL 3, 2023

old, for use by women with diabetes who are pregnant & for wear time of up to 15 days. of revenue in 2023 from its four in-line therapies & bringing Pfizer $10B+ in risk-adjusted revenues by 2030. The results also showed a reduction in risk of hospitalization for any cause with 14% relative risk reduction (24.8

Biosimilars 40

Biosimilars Diabetes Compounding Hospitals 40